Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Factors associated with cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation: human leukocyte antigens might be among the risk factors.

Acar K, Akı SZ, Ozkurt ZN, Bozdayı G, Rota S, Türköz Sucak G.

Turk J Haematol. 2014 Sep 5;31(3):276-85. doi: 10.4274/tjh.2013.0244.

2.

Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.

Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T.

Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.

3.

Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.

George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.

Transpl Infect Dis. 2010 Aug 1;12(4):322-9. doi: 10.1111/j.1399-3062.2010.00504.x. Epub 2010 May 11.

PMID:
20487414
4.

A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group.

George B, Kerridge IH, Gilroy N, Huang G, Hertzberg MS, Bradstock KF, Gottlieb DJ.

Transpl Infect Dis. 2012 Apr;14(2):141-8. doi: 10.1111/j.1399-3062.2011.00706.x. Epub 2012 Jan 29.

PMID:
22283838
5.

Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation.

Horowitz A, Guethlein LA, Nemat-Gorgani N, Norman PJ, Cooley S, Miller JS, Parham P.

J Immunol. 2015 Nov 1;195(9):4524-36. doi: 10.4049/jimmunol.1401990. Epub 2015 Sep 28.

6.

Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.

Lin TS, Zahrieh D, Weller E, Alyea EP, Antin JH, Soiffer RJ.

Transplantation. 2002 Jul 15;74(1):49-54.

PMID:
12134098
7.
8.

Relationship between HLA tissue type, CMV infection, and acute graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: single-center experience.

Kekik C, Besisik SK, Seyhun Y, Oguz FS, Sargin D, Carin MN.

Transplant Proc. 2009 Nov;41(9):3859-62. doi: 10.1016/j.transproceed.2009.04.017.

PMID:
19917401
9.

Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants.

Meijer E, Boland GJ, Verdonck LF.

Clin Microbiol Rev. 2003 Oct;16(4):647-57. Review.

10.

Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.

Borchers S, Luther S, Lips U, Hahn N, Kontsendorn J, Stadler M, Buchholz S, Diedrich H, Eder M, Koehl U, Ganser A, Mischak-Weissinger E.

Transpl Infect Dis. 2011 Jun;13(3):222-36. doi: 10.1111/j.1399-3062.2011.00626.x. Epub 2011 May 18.

PMID:
21585633
11.

Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.

Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R.

Biol Blood Marrow Transplant. 2014 Jan;20(1):46-52. doi: 10.1016/j.bbmt.2013.10.003. Epub 2013 Oct 10.

12.

Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.

Jaskula E, Dlubek D, Duda D, Bogunia-Kubik K, Mlynarczewska A, Lange A.

Biol Blood Marrow Transplant. 2009 Oct;15(10):1296-305. doi: 10.1016/j.bbmt.2009.06.008. Epub 2009 Aug 8.

13.

Impact of pretransplant donor and recipient cytomegalovirus serostatus on outcome for multiple myeloma patients undergoing reduced intensity conditioning allogeneic stem cell transplantation.

El-Cheikh J, Devillier R, Crocchiolo R, Fürst S, Calmels B, Faucher C, Stoppa AM, Granata A, Castagna L, Ladaique P, Lemarie C, Bouabdallah R, Zandotti C, Merlin M, Berger P, Chabannon C, Blaise D.

Mediterr J Hematol Infect Dis. 2013 Apr 10;5(1):e2013026. doi: 10.4084/MJHID.2013.026. Print 2013.

15.

Cytomegalovirus reactivation after matched sibling donor reduced-intensity conditioning allogeneic hematopoietic stem cell transplant correlates with donor killer immunoglobulin-like receptor genotype.

Sobecks RM, Askar M, Thomas D, Rybicki L, Kalaycio M, Dean R, Avery R, Mossad S, Copelan E, Bolwell BJ.

Exp Clin Transplant. 2011 Feb;9(1):7-13.

16.

Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation.

Junghanss C, Storb R, Maris MB, Carter RA, Sandmaier BM, Maloney DG, McSweeney PA, Corey L, Boeckh M.

Br J Haematol. 2003 Nov;123(4):662-70.

PMID:
14616970
17.

Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation.

Serio B, Rosamilio R, Giudice V, Pepe S, Zeppa P, Esposiito S, Pezzullo L, Rocco M, Montuori N, Selleri C.

Infez Med. 2012;20 Suppl 2:26-34.

18.

Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation.

Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P, White K, Corey L, Boeckh M.

Blood. 2003 Oct 15;102(8):3060-7. Epub 2003 Jul 3.

19.

Incidence and risk factors for cytomegalovirus (CMV) reactivation following autologous hematopoietic stem cell transplantation in children.

Hussein AA, Al-Antary ET, Najjar R, Al-Hamdan DS, Al-Zaben A, Frangoul H.

Pediatr Blood Cancer. 2015 Jun;62(6):1099-101. doi: 10.1002/pbc.25292. Epub 2014 Oct 24.

PMID:
25346146
20.

Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation.

Xiao Y, Song J, Jiang Z, Li Y, Gao Y, Xu W, Lu Z, Wang Y, Xiao H.

Int J Med Sci. 2014 Apr 30;11(6):652-7. doi: 10.7150/ijms.6337. eCollection 2014.

Supplemental Content

Support Center